查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984183

下一代乳癌診斷和篩檢市場：按產品、檢測類型、分期、應用和最終用戶分類—2026-2032年全球市場預測

Next-Generation Breast Cancer Diagnostic & Screening Market by Offerings, Test Type, Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計下一代乳癌診斷和篩檢市場在 2025 年的價值為 74.7 億美元，在 2026 年成長到 80.2 億美元，到 2032 年達到 128 億美元，複合年成長率為 7.99%。

主要市場統計數據
基準年 2025 74.7億美元
預計年份：2026年 80.2億美元
預測年份 2032 128億美元
複合年成長率 (%) 7.99%

這本入門書籍展望了下一代乳癌診斷的未來前景，並將其置於臨床實踐、技術整合和策略實施的必要性背景下進行討論。

在乳癌診斷和篩檢領域，技術、監管和臨床要素正以前所未有的程度相互交織，重新定義著該疾病的檢測、表徵和管理方式。影像學、分子檢測、數位病理學和微創切片檢查等領域的最新創新，已將臨床工作流程從單一模式轉變為以準確性、速度和以患者為中心的綜合診斷路徑。如今，臨床醫生和醫療系統所需的工具不僅能夠實現惡性腫瘤的早期發現，還能促進風險分層、預測治療反應，並在整個治療過程中進行高效監測。

影像、分子分析、數位病理學和分散式檢查等領域的技術進步如何重新定義乳癌的診斷途徑和策略重點。

由於多種因素加速了技術應用並重建了競爭優勢，這種情況正在改變。影像技術的進步，尤其是在解析度提高、人工智慧 (AI) 影像解讀和多模態融合的推動下，正在改善病灶表徵並減少以往阻礙診​​斷過程的假陽性結果。同時，分子診斷和液態生物檢體調查方法正在推動更精細的腫瘤分析，從而實現分子突變的早期檢測和更詳細的時間序列監測。數位病理平台和基於雲端的工作流程促進了遠端專家審查和演算法支持，而植入式感測器和穿戴式裝置則為持續監測生理指標和生物標記提供了可能。

基於證據的評估，探討 2025 年美國關稅措施將如何重塑乳癌診斷領域的供應鏈、籌資策略和創新動態。

美國2025年實施的一系列關稅措施的累積影響，正對供應鏈、採購成本和跨境合作造成複雜的壓力，並波及整個診斷和篩檢生態系統。診斷設備、成像組件和特殊試劑在生產和分銷過程中經常需要跨越多個國家。關稅會增加最終成本，並使醫院、診斷檢查室和專科診所在選擇供應商時更加複雜。為此，採購團隊正在審查供應商整合和近岸外包策略，以最大限度地減少對臨床營運的干擾，同時保持預算柔軟性。

策略性細分洞察揭示了產品陣容、測試方法、臨床階段重點、用例和最終用戶概況如何影響診斷技術的採用和優先排序。

基於細分市場的分析揭示了該領域臨床需求、技術成熟度和商業性機會的交匯點。對產品系列的分析表明，影像技術在解剖學檢測和風險分層中仍然發揮著核心作用，其中乳房X光攝影光攝影、磁振造影（MRI）和乳房超音波各自滿足不同的臨床需求。乳房X光攝影仍然是大規模篩檢的基礎，MRI在高風險和緻密型乳房病例中表現出色，超音波有助於病灶定性和引導介入治療。數位病理平台擴展了診斷處理能力，並實現了演算法分診。同時，包括微陣列、次世代定序和基於PCR的檢測在內的分子診斷技術，提供了個人化治療選擇和微量殘存疾病評估所需的分子水平解析度。植入式感測器和穿戴式裝置仍在發展中，但它們是實現連續生理監測的極具前景的手段，而液態生物檢體技術則為理解腫瘤基因組分析和動態變化提供了微創方法。

美洲、歐洲、中東、非洲和亞太地區在診斷技術的採用和政策方面存在差異，這決定了獲取、報銷和部署的優先事項。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的技術應用、報銷途徑和臨床重點產生了顯著影響。在美洲，醫療保健系統和保險公司日益鼓勵以價值為導向的醫療模式，重視早期發現和精準診斷，這推動了大規模學術醫療中心和私人醫療網路採用整合影像和分子診斷平台。在該地區的部分地區，監管和報銷環境支持快速採用具有可靠臨床證據支持的創新檢測方法，而商業策略通常強調與醫院網路和診斷實驗室建立合作關係，以確保獲得臨床病例。

科學差異化、監管策略、夥伴關係和供應鏈韌性如何決定診斷和篩檢解決方案供應商的競爭優勢。

診斷和篩檢生態系統的競爭動態是由科學差異化、監管進步、策略夥伴關係和商業化敏捷性這四者共同驅動的。領先企業優先考慮端到端價值，將高品質的檢測和醫療設備與軟體驅動的解讀和服務模式相結合，從而減輕臨床用戶的負擔。與學術機構和臨床網路的合作能夠加速循證醫學的產生，並支持其被納入臨床實踐指南；而與保險公司和醫療服務提供者的合作則有助於建立報銷機制，並在真實的臨床環境中檢驗其績效。

為診斷創新者和醫療保健系統領導者提供可操作和優先行動方案，以加速採用、降低商業化風險，並使證據與報銷途徑保持一致。

產業領導者必須採取果斷行動，將技術潛力轉化為永續的臨床和商業性價值。首先，他們應優先考慮整合產品策略，將高品質的診斷方法和醫療設備與分析軟體和服務等級協議相結合，從而降低臨床醫生和檢查室採用這些技術所面臨的障礙。其次，他們應投資於針對性臨床檢驗，直接解決診療路徑中的決策點。這不僅應展現分析性能，還應展現其在早期檢測、治療方法選擇和長期監測方面的臨床效用。第三，他們應透過供應商多元化、關鍵製造能力的地域分散以及建立緊急庫存管理方法來應對關稅和貿易波動，從而提高供應鏈透明度。

我們採用嚴謹且多方面的調查方法，結合與主要相關人員的對話、臨床文獻的整合、監管趨勢的分析和情境分析，得出了可靠的見解。

本分析所依據的研究基於多層次的調查方法，該方法整合了關鍵相關人員的意見、同行評審的臨床文獻、監管文件以及診斷服務供應商的營運資訊。主要研究包括對臨床醫生、檢查室管理人員、政策顧問和採購專家進行結構化訪談，以了解實際工作流程的限制、對證據的期望以及推廣應用的障礙。次要資訊包括已發布的監管文件、臨床指南、技術白皮書和近期學術文章，這些資料被用作技術評估的基礎，並用於檢驗臨床效用聲明。

全面概述診斷技術的演變，展示整合技術、證據策略和營運韌性如何決定臨床和商業性的成功。

乳癌診斷和篩檢的發展既反映了技術的成熟，也反映了以價值主導、以患者為中心的醫療體系的系統性重組。影像學、分子檢測、數位病理學和分散式檢查模式的進步並非孤立的創新，而是構成一個綜合診斷生態系統的組成部分，該生態系統支持早期發現、更精準的治療方法選擇和高效的監測。監管預期、報銷機制和供應鏈韌性等實際操作因素，將決定哪些技術能夠從「前景廣闊」走向「廣泛應用」。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：下一代乳癌診斷和篩檢市場：按產品/服務分類

  • 數位病理學
  • 醫學影像技術
    • 乳腺超音波檢查
    • 磁振造影
    • 乳房X光攝影
  • 嵌入式感測器
  • 液態生物檢體
  • 分子診斷
    • 微陣列
    • 次世代定序
    • 基於PCR的檢測
  • 穿戴式裝置

第9章 下一代乳癌診斷與篩檢市場：檢測類型

  • 基因檢測
    • BRCA基因檢測
    • 基因組分析
  • 病理檢查
    • 細胞學
    • 組織病理學
  • 蛋白質標記檢測
    • ER/PR 檢測
    • HER2檢測

第10章：下一代乳癌診斷與篩檢市場：按階段分類

  • 晚期
    • 第三階段
    • 第四階段
  • 早期的
    • 第一階段
    • 第二階段

第11章 下一代乳癌診斷與篩檢市場：按應用分類

  • 早期檢測
    • 定期乳房X光攝影
    • 自我檢查
  • 後續觀察
    • 復發
    • 治療反應
  • 健康檢查計劃

第12章 下一代乳癌診斷與篩檢市場：依最終用戶分類

  • 學術和研究機構
  • 診斷檢測實驗室
  • 醫院
  • 專科診所

第13章：下一代乳癌診斷與篩檢市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 下一代乳癌診斷與篩檢市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 下一代乳癌診斷和篩檢市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國下一代乳癌診斷與篩檢市場

第17章：中國下一代乳癌診斷與篩檢市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agendia Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Centogene NV
  • Danaher Corporation
  • Epic Sciences, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFF0

The Next-Generation Breast Cancer Diagnostic & Screening Market was valued at USD 7.47 billion in 2025 and is projected to grow to USD 8.02 billion in 2026, with a CAGR of 7.99%, reaching USD 12.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.47 billion
Estimated Year [2026] USD 8.02 billion
Forecast Year [2032] USD 12.80 billion
CAGR (%) 7.99%

A forward-looking primer that situates next-generation breast cancer diagnostics within clinical practice, technology convergence, and strategic adoption imperatives

The diagnostic and screening landscape for breast cancer is undergoing a rare confluence of technological, regulatory, and clinical forces that is redefining how disease is detected, characterized, and managed. In recent years, innovations in imaging, molecular assays, digital pathology, and minimally invasive sampling have shifted clinical workflows away from singular modalities toward integrated diagnostic pathways that emphasize precision, speed, and patient-centric access. Clinicians and health systems now demand tools that not only detect malignancy earlier but also stratify risk, predict treatment response, and enable streamlined monitoring across the continuum of care.

This introduction positions stakeholders to view next-generation diagnostics as more than incremental device or assay improvements. Instead, they represent architectural changes to care delivery: diagnostic data now informs therapeutic choices in near real time, digital platforms enable remote interpretation and triage, and decentralized testing models expand reach beyond traditional hospital systems. As we proceed through this analysis, the emphasis will remain on how technological maturity, clinical validation, reimbursement evolution, and supply chain resilience converge to influence adoption decisions and competitive positioning. Readers should expect evidence-based synthesis that prioritizes actionable implications for clinical, commercial, and policy leaders operating at the intersection of innovation and patient outcomes.

How technological advances in imaging, molecular profiling, digital pathology, and decentralized testing are redefining breast cancer diagnostic pathways and strategic priorities

The landscape is shifting along multiple vectors that collectively accelerate adoption and reconfigure competitive advantage. Advances in imaging technologies-driven by enhanced resolution, artificial intelligence-augmented interpretation, and multimodal integration-are improving lesion characterization and reducing false positives that traditionally burden diagnostic pathways. Concurrently, molecular diagnostics and liquid biopsy methodologies are transforming the granularity of tumor profiling, enabling earlier detection of molecular alterations and richer longitudinal monitoring. Digital pathology platforms and cloud-based workflows are facilitating remote expert review and algorithmic augmentation, while implantable sensors and wearable devices are introducing continuous physiologic and biomarker monitoring possibilities.

These technical shifts are accompanied by systemic changes. Health systems increasingly prioritize value-based outcomes that reward early detection and precise treatment selection, therefore creating incentives to deploy tools that demonstrably reduce unnecessary interventions and improve patient trajectories. Regulatory pathways are evolving to accommodate software as a medical device and genomic assays, which shortens paths to clinical use when supported by robust clinical evidence. At the same time, patient expectations for convenience and information access are pushing screening programs toward decentralized and hybrid models that blend at-home testing with point-of-care diagnostics. Together, these transformative shifts demand that stakeholders rethink product development roadmaps, evidence generation strategies, and commercialization plans to capture emerging opportunities and address new operational challenges.

An evidence-based assessment of how the 2025 United States tariff measures reshape supply chains, procurement strategies, and innovation dynamics in breast cancer diagnostics

The cumulative impact of tariff actions implemented by the United States in 2025 has introduced a complex set of pressures across supply chains, procurement costs, and cross-border collaborations that reverberate through diagnostic and screening ecosystems. Diagnostic instruments, imaging components, and specialized reagents frequently cross multiple borders during manufacture and distribution; tariffs increase landed cost and complicate vendor selection for hospitals, diagnostic laboratories, and specialty clinics. In response, procurement teams are reassessing supplier consolidation and nearshoring strategies to preserve budgetary flexibility while minimizing clinical disruption.

Beyond direct price effects, tariffs have amplified strategic re-evaluations of inventory management and contractual terms. Organizations that previously relied on just-in-time supply models are strengthening buffer stocks for critical reagents and imaging parts, and diagnostic manufacturers are diversifying manufacturing footprints to mitigate tariff exposure. Clinical research activities that depend on international assay kits and instrumentation face elongated timelines due to customs clearance variability, prompting sponsors to redesign trial logistics and localize certain assay processing where feasible.

Furthermore, tariffs influence innovation calculus. Companies that depend on cross-border component sourcing must allocate incremental capital to preserve margins, which can delay investments in validation studies or software enhancements. Conversely, some firms view the environment as an impetus to verticalize manufacturing and invest in domestic capabilities, a move that can accelerate local job creation and regulatory engagement but requires upfront capital and operational maturity. Ultimately, the tariff landscape is reshaping cost structures, partnership models, and operational resilience, encouraging stakeholders to adopt more robust scenario planning and supply-chain transparency.

Strategic segmentation insights revealing how offerings, test modalities, clinical stage focus, application use cases, and end-user profiles shape diagnostic adoption and prioritization

A segmentation-driven view of the field illuminates where clinical need, technological readiness, and commercial opportunity intersect. When offerings are parsed, imaging technologies remain central for anatomical detection and risk stratification, with mammography, magnetic resonance imaging, and breast ultrasound each fulfilling distinct clinical niches; mammography continues as the backbone of population screening, magnetic resonance imaging excels in high-risk and dense-breast contexts, and ultrasound complements both in lesion characterization and guided interventions. Digital pathology platforms are expanding diagnostic throughput and enabling algorithmic triage, while molecular diagnostics-encompassing microarrays, next-generation sequencing, and PCR-based assays-deliver the molecular resolution needed for personalized therapy selection and minimal residual disease assessment. Implantable sensors and wearable devices are nascent but promising vectors for continuous physiologic surveillance, and liquid biopsy technologies provide minimally invasive windows into tumor genomics and dynamics.

Examining test types yields further clarity on clinical workflows and investment priorities. Genetic tests such as BRCA analysis and broader genomic profiling are pivotal in hereditary risk assessment and targeted therapy selection, whereas pathological tests, including cytology and histopathology, remain indispensable for definitive diagnosis and staging. Protein marker testing, notably ER/PR assays and HER2 evaluation, continues to guide therapeutic decision-making and necessitates rigorous assay standardization. Stage-based segmentation differentiates early-stage needs-where routine mammograms and self-exams support early detection and curative intent-from advanced-stage priorities, which focus on monitoring stage III and IV disease for recurrence and treatment response. Application-focused distinctions highlight the divergent requirements of early detection programs, ongoing monitoring for recurrence or therapeutic efficacy, and organized screening programs that prioritize population-level reach and adherence.

Finally, end-user segmentation underscores operational realities: academic and research institutes drive translational validation and complex assay development, diagnostic laboratories scale throughput and ensure quality control, hospitals integrate diagnostics into multidisciplinary care pathways, and specialty clinics deliver focused services with rapid turnaround. Each end user demands tailored evidence, workflow integration, and economic justification, which in turn shapes product design, service models, and commercialization strategies.

Regional diagnostic adoption and policy variance across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine access, reimbursement, and deployment priorities

Regional dynamics materially influence technology adoption, reimbursement pathways, and clinical priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, health systems and payers increasingly incentivize value-based approaches that reward early detection and precision diagnostics, propelling adoption of integrated imaging and molecular platforms within large academic centers and private networks. The regulatory and reimbursement environment in parts of the region supports rapid adoption of innovative assays when supported by robust clinical evidence, and commercial strategies frequently emphasize partnerships with hospital networks and diagnostic laboratories to secure clinical volume.

Across Europe, Middle East and Africa, heterogeneity in regulatory regimes and healthcare financing creates a patchwork of adoption pathways. High-income European markets often demonstrate rapid uptake of validated molecular diagnostics and AI-enhanced imaging, while other jurisdictions prioritize access and cost-effectiveness, influencing the balance between population screening programs and targeted high-risk interventions. Regulatory harmonization efforts and cross-border clinical collaborations in the region help streamline multicenter validation studies, yet logistical complexity and variable infrastructure require adaptable deployment models.

The Asia-Pacific region presents a mix of large-scale public screening initiatives and fast-growing private healthcare sectors, with particular emphasis on scalable, cost-efficient technologies that can serve diverse populations. Rapid urbanization and investments in digital health are enabling telepathology and AI-enabled imaging platforms to expand reach, while regional manufacturing hubs are increasingly important for supply chain resilience. Across all regions, localized evidence generation, culturally appropriate patient engagement, and alignment with national screening policies remain critical determinants of long-term uptake.

How scientific differentiation, regulatory strategy, partnerships, and supply-chain resilience combine to define competitive advantage among diagnostic and screening solution providers

Competitive dynamics in the diagnostics and screening ecosystem are driven by the intersection of scientific differentiation, regulatory progress, strategic partnerships, and commercialization agility. Leading organizations prioritize end-to-end value by combining high-quality assays or devices with software-enabled interpretation and service models that reduce friction for clinical users. Collaboration with academic centers and clinical networks accelerates evidence generation and supports guideline inclusion, while alliances with payers and providers help establish reimbursement pathways and real-world performance validation.

Innovation strategies vary: some companies focus on deep specialization, advancing proprietary assay chemistry, sequencing platforms, or sensor technologies to create defensible niches. Others pursue horizontal integration, bundling imaging, molecular, and digital pathology capabilities to offer comprehensive diagnostic solutions. Commercial rigor matters: organizations that invest in robust regulatory strategies, post-market surveillance, and clinician education consistently realize higher adoption rates. Additionally, supply-chain resilience and manufacturing flexibility now function as competitive advantages given recent trade and tariff dynamics, prompting firms to diversify sourcing, localize production, and strengthen distributor relationships. Ultimately, players that align scientific innovation with pragmatic deployment strategies and evidence-led payer engagement position themselves to capture clinical trust and long-term commercial viability.

Practical, prioritized actions for diagnostic innovators and health system leaders to accelerate adoption, de-risk commercialization, and align evidence with reimbursement pathways

Industry leaders must act decisively to convert technological promise into sustainable clinical and commercial value. First, prioritize integrated product strategies that combine high-quality assays or devices with interpretive software and service-level agreements that lower adoption friction for clinicians and laboratories. Second, invest in targeted clinical validation that maps directly to decision points in care pathways; demonstrate not only analytic performance but also clinical utility in early detection, treatment selection, and longitudinal monitoring. Third, strengthen supply-chain transparency by diversifying suppliers, regionalizing critical manufacturing capacity, and establishing contingency inventory practices to manage tariff and trade volatility.

Leaders should also cultivate payer and provider partnerships early in development to align evidence generation with reimbursement expectations and real-world performance measures. Embrace modular commercialization approaches that allow rapid piloting within academic centers and specialty clinics while scaling to larger hospital networks and national screening programs. Finally, invest in workforce and clinician education to ensure new technologies integrate into existing workflows without imposing additional operational burden. These measures, when implemented together, enhance adoption probability, mitigate regulatory and commercial risk, and accelerate the translation of diagnostic innovation into measurable patient benefit.

A rigorous, multi-source research methodology combining primary stakeholder engagement, clinical literature synthesis, regulatory mapping, and scenario analysis for robust insights

The research underpinning this analysis relies on a layered methodology that integrates primary stakeholder input, peer-reviewed clinical literature, regulatory documentation, and operational intelligence from diagnostic providers. Primary research included structured interviews with clinicians, laboratory directors, policy advisors, and procurement specialists to capture real-world workflow constraints, evidence expectations, and adoption barriers. Secondary sources comprised public regulatory filings, clinical guidelines, technology white papers, and recent academic publications to ground technical assessments and validate clinical utility claims.

Data were triangulated across sources to identify consistent themes and reconcile divergent perspectives. Scenario analysis evaluated supply-chain and tariff implications under alternative operational responses, while regulatory pathway mapping clarified approval and post-market obligations across major jurisdictions. Quality control measures included iterative expert review and validation of key inferences with domain specialists. Ethical considerations, including patient privacy and equitable access, informed interpretation of decentralized and at-home testing models. Together, these methodological elements ensured a balanced synthesis that links technological readiness to clinical, commercial, and policy realities.

A synthesis of diagnostic evolution showing how integrated technologies, evidence strategies, and operational resilience will determine clinical and commercial success

The evolution of breast cancer diagnostics and screening reflects both technological maturation and systemic realignment toward value-driven, patient-centered care. Imaging advances, molecular assays, digital pathology, and decentralized testing models are not isolated innovations but components of an integrated diagnostic ecosystem that supports earlier detection, more precise treatment selection, and efficient monitoring. Operational realities-regulatory expectations, reimbursement frameworks, and supply-chain resilience-will determine which technologies move from promising to pervasive.

Stakeholders that invest in rigorous evidence generation, flexible commercialization models, and resilient operational strategies will capture disproportionate clinical and commercial benefit. Equally important is alignment with regional policy priorities and provider workflows to ensure that diagnostics enhance, rather than complicate, care delivery. As the field advances, continuous collaboration between innovators, clinicians, payers, and regulators will be essential to translate technological potential into improved patient outcomes and system-level value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Offerings

  • 8.1. Digital Pathology
  • 8.2. Imaging Technologies
    • 8.2.1. Breast Ultrasound
    • 8.2.2. Magnetic Resonance Imaging
    • 8.2.3. Mammography
  • 8.3. Implantable Sensors
  • 8.4. Liquid Biopsy
  • 8.5. Molecular Diagnostics
    • 8.5.1. Microarrays
    • 8.5.2. Next-Generation Sequencing
    • 8.5.3. PCR-Based Assays
  • 8.6. Wearable Devices

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Test Type

  • 9.1. Genetic Tests
    • 9.1.1. BRCA Testing
    • 9.1.2. Genomic Profiling
  • 9.2. Pathological Tests
    • 9.2.1. Cytology
    • 9.2.2. Histopathology
  • 9.3. Protein Marker Tests
    • 9.3.1. ER/PR Tests
    • 9.3.2. HER2 Tests

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by Stage

  • 10.1. Advanced Stage
    • 10.1.1. Stage III
    • 10.1.2. Stage IV
  • 10.2. Early Stage
    • 10.2.1. Stage I
    • 10.2.2. Stage II

11. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

  • 11.1. Early Detection
    • 11.1.1. Routine Mammograms
    • 11.1.2. Self-Exams
  • 11.2. Monitoring
    • 11.2.1. Recurrence
    • 11.2.2. Treatment Response
  • 11.3. Screening Programs

12. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Next-Generation Breast Cancer Diagnostic & Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Next-Generation Breast Cancer Diagnostic & Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Next-Generation Breast Cancer Diagnostic & Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Next-Generation Breast Cancer Diagnostic & Screening Market

17. China Next-Generation Breast Cancer Diagnostic & Screening Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agendia Inc.
  • 18.7. Agilent Technologies, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. BGI Genomics Co., Ltd.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Centogene N.V.
  • 18.12. Danaher Corporation
  • 18.13. Epic Sciences, Inc.
  • 18.14. Exact Sciences Corporation
  • 18.15. F. Hoffmann-La Roche Ltd.
  • 18.16. Fujifilm Holdings Corporation
  • 18.17. GE HealthCare Technologies, Inc.
  • 18.18. Hologic, Inc.
  • 18.19. Illumina, Inc.
  • 18.20. Invivoscribe, Inc.
  • 18.21. Koninklijke Philips N.V.
  • 18.22. Laboratory Corporation of America Holdings
  • 18.23. Merck & Co., Inc.
  • 18.24. Myriad Genetics, Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer Inc.
  • 18.27. Siemens Healthineers AG
  • 18.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2032 (